Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

32.03B

Market cap32.03B

Price-Earnings ratio

38.39

Price-Earnings ratio38.39

Dividend yield

—

Dividend yield—

Average volume

757.67K

Average volume757.67K

High today

—

High today—

Low today

—

Low today—

Open price

$217.76

Open price$217.76

Volume

0.00

Volume0.00

52 Week high

$222.15

52 Week high$222.15

52 Week low

$131.52

52 Week low$131.52

Stock Snapshot

The current Biogen(BIIB) stock price is $216.78, with a market capitalization of 32.03B. The stock trades at a price-to-earnings (P/E) ratio of 38.39.

During the trading day, Biogen(BIIB) stock saw an opening price of $217.76, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 757.67K.

The stock's 52-week range extends from a low of $131.52 to a high of $222.15.

BIIB News

TipRanks 9m

Biogen, Eisai announce Leqembi Iqlik now available in U.S.

Eisai (ESAIY) and Biogen (BIIB), announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early...

Simply Wall St 2d

How Investors Are Reacting To Biogen Raising EPS Guidance On Late-Stage Drug Trial Milestones - simplywall.st

...

TipRanks 3d

Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Analyst ratings

67%

of 36 ratings

Buy

66.7%

Hold

30.6%

Sell

2.8%

More BIIB News

Simply Wall St 4d

Biogen And The Alzheimer’s Narrative As Valuation Stays In Focus

Biogen (BIIB) is back in focus after recent share price moves and fresh attention on its neurology focused drug portfolio. Investors are weighing current perfor...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.